M
Mauro Salizzoni
Researcher at University of Turin
Publications - 195
Citations - 10611
Mauro Salizzoni is an academic researcher from University of Turin. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 48, co-authored 194 publications receiving 9280 citations.
Papers
More filters
Journal ArticleDOI
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro,Josep M. Llovet,Rosalba Miceli,Sherrie Bhoori,M. Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K. Burroughs,Roberto Troisi,Massimo Rossi,Giorgio Enrico Gerunda,Jan Lerut,Jacques Belghiti,Ilka de Fátima Santana Ferreira Boin,Jean Gugenheim,Fedja Rochling,Bart van Hoek,Pietro Majno +27 more
TL;DR: More patients with hepatocellular carcinoma could be candidates for transplantation if the current dual approach to candidacy, based on the strict Milan criteria, were replaced with a more precise estimation of survival contouring individual tumour characteristics and use of the up-to-seven criteria.
Journal ArticleDOI
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)
René Adam,Vincent Karam,Valérie Delvart,John O'Grady,Darius F. Mirza,Jürgen Klempnauer,Denis Castaing,Peter Neuhaus,Neville V. Jamieson,Mauro Salizzoni,Stephen Pollard,Jan Lerut,Andreas Paul,Juan Carlos García-Valdecasas,Fernando San Juan Rodríguez,Andrew K. Burroughs +15 more
TL;DR: All data since 1968 are considered to show the evolu-tion of results of LT in Europe since its initial development and to demonstrate the reliability of ELTR data.
Journal ArticleDOI
Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure
Achilles A. Demetriou,Robert S. Brown,Ronald W. Busuttil,Jeffrey H. Fair,Brendan M. McGuire,Philip J. Rosenthal,Jan Schulte am Esch,Jan Lerut,Scott L. Nyberg,Mauro Salizzoni,Elizabeth A. Fagan,Bernard de Hemptinne,Christoph E. Broelsch,Maurizio Muraca,Joan Manuel Salmerón,John M. Rabkin,Herold J. Metselaar,Daniel S. Pratt,Manuel de la Mata,Lawrence P. McChesney,Gregory T. Everson,Philip T. Lavin,Anthony C. Stevens,Zorina Pitkin,Barry A. Solomon +24 more
TL;DR: This is the first prospective, randomized, controlled trial of an extracorporeal liver support system, demonstrating safety and improved survival in patients with fulminant/subfulminant hepatic failure.
Journal ArticleDOI
Evolution of liver transplantation in Europe: Report of the European liver transplant registry
René Adam,Paul McMaster,John O'Grady,Denis Castaing,Jürgen Klempnauer,Neville V. Jamieson,Peter Neuhaus,Jan Lerut,Mauro Salizzoni,Stephen Pollard,Ferdinand Mühlbacher,Xavier Rogiers,Juan Carlos Garcia Valdecasas,Joaquín Berenguer,Daniel Jaeck,Enrique Moreno González +15 more
TL;DR: One of the most important findings in the evolution of LT is the considerable improvement of results along time with, for the mean time, a one‐year survival of 83%, all indications confounded.
Journal ArticleDOI
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti,Eniko Papp,Siân Jones,Vilmos Adleff,Valsamo Anagnostou,Barbara Lupo,Mark Sausen,Jillian Phallen,Carolyn Hruban,Collin Tokheim,Noushin Niknafs,Monica Nesselbush,Karli Lytle,Francesco Sassi,Francesca Cottino,Giorgia Migliardi,Eugenia R. Zanella,Dario Ribero,Nadia Russolillo,A. Mellano,Andrea Muratore,Gianluca Paraluppi,Mauro Salizzoni,Silvia Marsoni,Michael Kragh,Johan Lantto,Andrea Cassingena,Qing Kay Li,Rachel Karchin,Robert B. Scharpf,Andrea Sartore-Bianchi,Salvatore Siena,Luis A. Diaz,Livio Trusolino,Victor E. Velculescu +34 more
TL;DR: A systematic approach to evaluating response to targeted therapies in human cancer is provided, new mechanisms of responsiveness to anti-EGFR therapies are highlighted, and new avenues for intervention in managing colorectal cancer are delineated.